文献速递中医内科中药与中成药合理使用

稳心颗粒:化学成分、药理活性、质量控制及临床应用综述

Chinese patent medicine Wenxin Keli: A review on its chemical constituents, pharmacological activities, quality control, and clinical applications.
PubMed 文献 · J Ethnopharmacol · 2026-05-08

本文综述了稳心颗粒的化学成分、质量控制、药理活性、安全性及临床应用,检索PubMed、Web of Science、Google Scholar、CNKI和万方数据库至2025年,遵循PRISMA指南。研究表明稳心颗粒治疗心血管疾病有效且不良反应较少,通过抗炎、抗氧化应激、调节心肌离子通道稳态、抑制凋亡及预防心肌缺血、心脏纤维化和心肌肥厚等多机制发挥治疗作用,但仍需更多临床试验和动物研究进一步验证疗效并指导临床应用。

要点

  • 稳心颗粒对心血管疾病患者有效,且不良反应相对较少。
  • 稳心颗粒通过抗炎、抗氧化应激、调节心肌离子通道稳态等多机制发挥治疗作用。
  • 仍需更多临床试验和动物研究进一步证实其疗效并指导临床应用。

核心结论

  • 稳心颗粒通过抗炎、抗氧化应激、调节心肌离子通道稳态、抑制凋亡及预防心肌缺血、心脏纤维化和心肌肥厚等多机制发挥心血管治疗作用。
  • 稳心颗粒治疗心血管疾病有效且不良反应相对较少,但仍需更多临床试验和动物研究进一步证实疗效并指导临床应用。

研究设计与样本

  • 综述检索PubMed、Web of Science、Google Scholar、中国知网和万方数据库至2025年的文献,检索过程遵循PRISMA指南。

主要发现

  • 既往研究表明稳心颗粒治疗心血管疾病患者有效,且不良反应相对较少。
  • 综述阐述了稳心颗粒抗心血管疾病效应与氧化应激、炎症、心肌离子通道等机制的关系,并总结了其安全性证据。

临床怎么用

  • 稳心颗粒可用于心血管疾病治疗,具有疗效且不良反应相对较少,但临床应用仍需更多临床试验和动物研究进一步验证。

局限性

  • 仍需更多临床试验和动物研究进一步证实稳心颗粒的疗效并指导临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, placing a substantial economic burden on both individuals and societies. In recent years, traditional Chinese medicine (TCM) has attracted increasing attention for its advantages in treating CVD, owing to its efficacy and relatively few side effects. Among various TCM formulations, Wenxin Keli (WXKL) has demonstrated promising therapeutic efficacy in the treatment of CVD. AIM OF THE REVIEW: This paper presents a comprehensive summary of the chemical composition, quality control, pharmacological activities, safety profile and clinical applications of WXKL, derived from extensive literature searches in major electronic databases. Furthermore, the current challenges facing WXKL and future perspectives for future research are discussed. MATERIALS AND METHODS: A comprehensive literature search was performed in the following electronic databases up to 2025: PubMed, Web of Science, Google Scholar, China National Knowledge Infrastructure, and WANFANG Data. The review process was conducted in accordance with the PRISMA guidelines. RESULTS: Previous studies indicate that WXKL is effective in treating patients with CVD and is associated with comparatively fewer adverse reactions. This review aims to elucidate the relationship between the anti-CVD effects of WXKL and mechanisms involving oxidative stress, inflammation, myocardial ion channels and other factors, while also summarizing current evidence regarding its safety profile. CONCLUSIONS: WXKL exerts therapeutic effects in CVD treatment through multiple mechanisms including anti-inflammatory and anti-oxidant stress, modulation of myocardial ion channel homeostasis, inhibition of apoptosis, and prevention of myocardial ischemia, cardiac fibrosis and cardiac hypertrophy. However, additional clinical trials and animal studies are still required to further substantiate its efficacy and guide clinical application. This review summarizes current research on WXKL and aims to provide insights to inform future investigations.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Shi H, Xie Y, et al. Chinese patent medicine Wenxin Keli: A review on its chemical constituents, pharmacological activities, quality control, and clinical applications. J Ethnopharmacol. 2026. PMID: 42107752. doi:10.1016/j.jep.2026.121815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。